Sandu Pharma.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE751D01014
NSEID:
BSEID: 524703

INR

38.74

0.71 (1.87%)

BSENSE

Dec 30

BSE+NSE Vol: 4.48 k

{
  "main_header": {
    "sid": 764862,
    "name": "Sandu Pharma.",
    "stock_name": "Sandu Pharma.",
    "full_name": "Sandu Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/sandu-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "38.74",
    "chg": 0.71,
    "chgp": "1.87%",
    "dir": 1,
    "prev_price": "38.03",
    "mcapval": "37.43 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524703,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "indexname": "",
    "isin": "INE751D01014",
    "curr_date": "Dec 30",
    "curr_time": "",
    "bse_nse_vol": "4.48 k",
    "exc_status": "Active",
    "traded_date": "Dec 30, 2025",
    "traded_date_str": "2025 12 30",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sandu-pharma-764862-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Sandu Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-is-rated-strong-sell-3771273",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/SanduPharmaceut_mojoScore_3771273.png",
        "date": "2025-12-26 15:12:03",
        "description": "Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 September 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 December 2025, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.36.76 Amidst Continued Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-falls-to-52-week-low-of-rs3676-3756336",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/SanduPharmaceut_priceRelatedfactors_3756336.png",
        "date": "2025-12-11 10:00:18",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low of Rs.36.76, marking a significant decline in its stock price amid ongoing challenges in its financial performance and market positioning within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Sandu Pharma. Sees Revision in Market Evaluation Amidst Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharma-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3750189",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/SanduPharma_mojoScore_3750189.png",
        "date": "2025-12-07 10:10:03",
        "description": "Sandu Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. This shift follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, underscoring the complexities faced by the stock in recent periods."
      },
      {
        "title": "Why is Sandu Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sandu-pharma-fallingrising-3747239",
        "imagepath": "",
        "date": "2025-12-05 00:53:47",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Sandu Pharmaceuticals recorded a gain of ₹0.89 per share on 04-Dec, marking a 2.25% increase. This rise follows two consecutive days of gains, during which the stock has appreciated by 2.28%. Notably, the stock outperformed its sector by 2.23% on the day, signalling a positive shift in investor sentiment within its industry segment. However, the stock’s current price remains below its 20-day, 50-day, 100-day, and 200-day moving averages, although it is trading above the 5-day moving average. This technical positioning suggests that while short-term momentum is improving, the stock has yet to regain strength over longer time horizons.</p>\n<p><strong>Comparative Returns Against Benchmarks</strong></p>\n<p>Examining Sandu Pharmaceuticals’ ..."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.01 Amidst Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-falls-to-52-week-low-of-rs3701-3735027",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3735027.png",
        "date": "2025-11-28 09:48:44",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid broader market activity. The stock’s performance contrasts with the overall positive trend in the Sensex, highlighting ongoing challenges within the company’s financial and operational metrics."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.01 Amidst Continued Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-falls-to-52-week-low-of-rs3701-3735029",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3735029.png",
        "date": "2025-11-28 09:48:30",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid ongoing challenges in its financial performance and market positioning within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.21 Amid Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-hits-52-week-low-amidst-continued-downtrend-3729278",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3729278.png",
        "date": "2025-11-25 15:42:29",
        "description": "Sandu Pharmaceuticals touched a fresh 52-week low of Rs.37.21 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past three consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.21 Amid Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-falls-to-52-week-low-of-rs3721-3729276",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3729276.png",
        "date": "2025-11-25 15:42:28",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.21 today, marking a significant decline amid broader market fluctuations and sector underperformance. The stock has experienced a notable downward trend over the past three days, reflecting ongoing challenges within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is Sandu Pharma. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sandu-pharma-overvalued-or-undervalued-3716743",
        "imagepath": "",
        "date": "2025-11-20 08:06:19",
        "description": "As of 19 November 2025, Sandu Pharma's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 25.21, an EV to EBITDA of 13.51, and a Price to Book Value of 0.94, which suggest that the stock is trading at a reasonable price relative to its earnings and book value.\n\nIn comparison to its peers, Sandu Pharma's valuation appears favorable. For instance, Elitecon International is categorized as very expensive with a PE Ratio of 265.8, while PTC India, deemed very attractive, has a significantly lower PE Ratio of 7.5. Despite recent underperformance, with a year-to-date return of -28.92% compared to the Sensex's 9.02%, the attractive valuation grade and competitive ratios position Sandu Pharma as a potential buying opportunity in the pharmaceuticals and b..."
      }
    ],
    "total": 81,
    "sid": "764862",
    "stock_news_url": "https://www.marketsmojo.com/news/sandu-pharmaceuticals-764862"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "24-Dec-2025",
      "details": "Intimation about the closure of trading window for Q ended 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement Under Regulation 30-Notice Intimating Discrepancies By Government Of Maharashtra Department Of Goods And Service Tax-Office Of The Deputy Commissioner Of The State Of Goa",
      "datetime": "22-Dec-2025",
      "details": "intimation about the Notice Pertaining to discrepancies by Government of Maharashtra department of Goods and service Tax",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot",
      "datetime": "19-Nov-2025",
      "details": "Outcome of the Postal Ballot pertaining to reclassification of M/s Akshath Finvest and Properties Private Limited from Promoter Group category to Public category",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sandu Pharmaceuticals Ltd has declared <strong>8%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Sandu Pharmaceuticals Ltd is Rated Strong Sell

2025-12-26 15:12:03

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 September 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 December 2025, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.36.76 Amidst Continued Underperformance

2025-12-11 10:00:18

Sandu Pharmaceuticals has reached a new 52-week low of Rs.36.76, marking a significant decline in its stock price amid ongoing challenges in its financial performance and market positioning within the Pharmaceuticals & Biotechnology sector.

Sandu Pharma. Sees Revision in Market Evaluation Amidst Challenging Fundamentals

2025-12-07 10:10:03

Sandu Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. This shift follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, underscoring the complexities faced by the stock in recent periods.

Why is Sandu Pharma. falling/rising?

2025-12-05 00:53:47

Recent Price Movement and Market Context

Sandu Pharmaceuticals recorded a gain of ₹0.89 per share on 04-Dec, marking a 2.25% increase. This rise follows two consecutive days of gains, during which the stock has appreciated by 2.28%. Notably, the stock outperformed its sector by 2.23% on the day, signalling a positive shift in investor sentiment within its industry segment. However, the stock’s current price remains below its 20-day, 50-day, 100-day, and 200-day moving averages, although it is trading above the 5-day moving average. This technical positioning suggests that while short-term momentum is improving, the stock has yet to regain strength over longer time horizons.

Comparative Returns Against Benchmarks

Examining Sandu Pharmaceuticals’ ...

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.01 Amidst Market Pressure

2025-11-28 09:48:44

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid broader market activity. The stock’s performance contrasts with the overall positive trend in the Sensex, highlighting ongoing challenges within the company’s financial and operational metrics.

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.01 Amidst Continued Underperformance

2025-11-28 09:48:30

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid ongoing challenges in its financial performance and market positioning within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.21 Amid Continued Downtrend

2025-11-25 15:42:29

Sandu Pharmaceuticals touched a fresh 52-week low of Rs.37.21 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past three consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.21 Amid Market Pressure

2025-11-25 15:42:28

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.21 today, marking a significant decline amid broader market fluctuations and sector underperformance. The stock has experienced a notable downward trend over the past three days, reflecting ongoing challenges within the Pharmaceuticals & Biotechnology sector.

Is Sandu Pharma. overvalued or undervalued?

2025-11-20 08:06:19

As of 19 November 2025, Sandu Pharma's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 25.21, an EV to EBITDA of 13.51, and a Price to Book Value of 0.94, which suggest that the stock is trading at a reasonable price relative to its earnings and book value. In comparison to its peers, Sandu Pharma's valuation appears favorable. For instance, Elitecon International is categorized as very expensive with a PE Ratio of 265.8, while PTC India, deemed very attractive, has a significantly lower PE Ratio of 7.5. Despite recent underperformance, with a year-to-date return of -28.92% compared to the Sensex's 9.02%, the attractive valuation grade and competitive ratios position Sandu Pharma as a potential buying opportunity in the pharmaceuticals and b...

View All News

Announcement

Closure of Trading Window

24-Dec-2025 | Source : BSE

Intimation about the closure of trading window for Q ended 31st December 2025

Announcement Under Regulation 30-Notice Intimating Discrepancies By Government Of Maharashtra Department Of Goods And Service Tax-Office Of The Deputy Commissioner Of The State Of Goa

22-Dec-2025 | Source : BSE

intimation about the Notice Pertaining to discrepancies by Government of Maharashtra department of Goods and service Tax

Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

19-Nov-2025 | Source : BSE

Outcome of the Postal Ballot pertaining to reclassification of M/s Akshath Finvest and Properties Private Limited from Promoter Group category to Public category